Clinical Trial Update: Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating docetaxel chemotherapy in combination with pembrolizumab and interleukin-12 gene therapy for triple-negative breast cancer w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Interleukin-12 gene therapy (interleukin-12 gene therapy)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Triple Negative Breast Cancer, Anthracycline-refractory TNBC | Phase 2 | Status: TERMINATED | Results posted: 2026-01-23